Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | TP53 | P04637 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.92 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.81 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5296604 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL3219205 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5306145 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5296135 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL2872711 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5291412 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5287942 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5296028 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL5293588 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL22806629 | 1.00 | SLC22A1 (1.00) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225543-B2 | Softening thermoplastic polyurethanes using ionomer technology | THE UNIVERSITY OF AKRON (US) | 2022-01-18 | — | — | US | claimed |
| US-11041039-B2 | Softening thermoplastic polyurethanes using ionomer technology | COVESTRO LLC (US) | 2021-06-22 | — | — | US | claimed |
| US-20190217159-A1 | GOLF BALL COMPOSITIONS COMPRISING THERMOPLASTIC POLYURETHANE IONOMERS | ACUSHNET COMPANY (US) | 2019-07-18 | — | — | US | claimed |
| US-20190211131-A1 | SOFTENING THERMOPLASTIC POLYURETHANES USING IONOMER TECHNOLOGY | LLC COVESTRO (US) | 2019-07-11 | — | — | US | claimed |
| US-20190185609-A1 | SOFTENING THERMOPLASTIC POLYURETHANES USING IONOMER TECHNOLOGY | UNIV AKRON (US) | 2019-06-20 | — | — | US | claimed |
| US-10245470-B1 | Golf ball compositions comprising thermoplastic polyurethane ionomers | ACUSHNET COMPANY (US) | 2019-04-02 | — | — | US | claimed |
| US-9983162-B2 | Method and device for detection of bioavailable drug concentration | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | claimed |
| US-20160347900-A1 | SOFTENING THERMOPLASTIC POLYURETHANES USING IONOMER TECHNOLOGY | THE UNIVERSITY OF AKRON | 2016-12-01 | — | — | US | claimed |
| EP-1825913-B1 | New catalyst systems and their application for metathesis reactions | LANXESS DEUTSCHLAND GMBH (DE) | 2016-08-17 | — | — | EP | claimed |
| US-20150119848-A1 | METHOD AND DEVICE FOR DETECTION OF BIOAVAILABLE DRUG CONCENTRATION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-04-30 | — | — | US | claimed |
| US-20110227047-A1 | ORGANIC PHOTOELECTRIC SEMICONDUCTOR DEVICE AND METHOD FOR FABRICATING THE SAME | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2011-09-22 | — | — | US | claimed |
| US-20110077360-A1 | PROCESS FOR REACTING CHEMICAL COMPOUNDS IN THE PRESENCE OF CATALYST SYSTEMS | LANXESS DEUTSCHLAND GMBH (DE) | 2011-03-31 | — | — | US | claimed |
| US-20070208206-A1 | Novel catalyst systems and a process for reacting chemical compounds in the presence of said catalyst systems | LANXESS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | claimed |
| EP-1825913-A1 | New catalyst systems and their application for metathesis reactions | Lanxess Deutschland GmbH & Co.KG (DE) | 2007-08-29 | — | — | EP | claimed |
| EP-1435369-B1 | composition for preparing porous dielectric films | SAMSUNG ELECTRONICS CO LTD (KR) | 2007-02-07 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0615857-B1 | Recording sheets containing monoammonium compounds | XEROX CORP (US) | 1998-11-11 | — | — | EP | claimed |
| US-5739230-A | CURABLE THROUGH A MICHAEL REACTION BETWEEN A COMPONENT HAVING A PLURALITY OF ALPHA,BETA-UNSATURATED CARBONYL GROUPS AND A COMPONENT HAVING A PLURALITY OF ACTIVATED METHYLENE GROUPS | NIPPON PAINT CO., LTD. (JP) | 1998-04-14 | — | — | US | claimed |
| EP-0300364-B1 | CHLORIDE ION-SELECTIVE ELECTRODE | HITACHI, LTD. (JP) | 1992-09-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208206-A1 | Novel catalyst systems and a process for reacting chemical compounds in the presence of said catalyst systems | NBAS, NNMT, CAT | SLC22A1 4788/4885ALDH1A1 2504/4885TP53 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.